trending Market Intelligence /marketintelligence/en/news-insights/trending/E9MVa6ztndMWdOIP58bkYA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Mirati Therapeutics starts $75M underwritten public offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Mirati Therapeutics starts $75M underwritten public offering

Mirati Therapeutics Inc. started a $75 million underwritten public offering of its common shares.

The San Diego-based biotechnology company will give underwriters an option to buy up to an additional $11.3 million in shares.

J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Cowen and Co. LLC, Barclays Capital Inc. and Credit Suisse Securities (USA) LLC are offering's joint book-running managers.

Mirati Therapeutics develops drugs that target genetic changes in cancer cells which cause tumors to grow and spread.